Pharmaxis: A Star Performer at Commercialization Crossroads Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Pharmaxis: A Star Performer at Commercialization Crossroads case study

At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Pharmaxis: A Star Performer at Commercialization Crossroads case study is a Harvard Business School (HBR) case study written by Deepak Sardana, Don Scott-Kemmis. The Pharmaxis: A Star Performer at Commercialization Crossroads (referred as “Pharmaxis Commercialization” from here on) case study provides evaluation & decision scenario in field of Strategy & Execution. It also touches upon business topics such as - Value proposition, Strategic planning.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment

---

Case Description of Pharmaxis: A Star Performer at Commercialization Crossroads Case Study

Pharmaxis is a new biotechnology venture based in Sydney, Australia. Brings to light the important stages in the growth of the company and the commercialization decisions the company faced. Highlights both the uniqueness of some of the managing team's decisions and their understanding of the industry and underscores the point that good decision-making can overcome apparent barriers to growth. The company is now at a key decision point. It needs to determine the best approach to commercialize its first diagnostic product. The wrong decision could waste scarce financial resources, divert the time of managers and researchers, and jeopardize the reputation of the firm with potential investors.

Case Authors : Deepak Sardana, Don Scott-Kemmis

Topic : Strategy & Execution

Related Areas : Strategic planning

---

Calculating Net Present Value (NPV) at 6% for Pharmaxis: A Star Performer at Commercialization Crossroads Case Study

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 6 %	Discounted Cash Flows
Year 0	(10008770)	-10008770	-	-
Year 1	3461520	-6547250	3461520	0.9434	3265585
Year 2	3982295	-2564955	7443815	0.89	3544228
Year 3	3960119	1395164	11403934	0.8396	3324992
Year 4	3250596	4645760	14654530	0.7921	2574776
TOTAL			14654530		12709582

The Net Present Value at 6% discount rate is 2700812

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting

What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.

---

Capital Budgeting Approaches

Methods of Capital Budgeting

There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Net Present Value
2. Payback Period
3. Profitability Index
4. Internal Rate of Return

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Timing of the expected cash flows – stockholders of Pharmaxis Commercialization have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.
2. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Pharmaxis Commercialization shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.

---

Formula and Steps to Calculate Net Present Value (NPV) of Pharmaxis: A Star Performer at Commercialization Crossroads

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Strategy & Execution Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Pharmaxis Commercialization often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Pharmaxis Commercialization needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 15 %	Discounted Cash Flows
Year 0	(10008770)	-10008770	-	-
Year 1	3461520	-6547250	3461520	0.8696	3010017
Year 2	3982295	-2564955	7443815	0.7561	3011187
Year 3	3960119	1395164	11403934	0.6575	2603843
Year 4	3250596	4645760	14654530	0.5718	1858539
TOTAL					10483586

The Net NPV after 4 years is 474816

(10483586 - 10008770 )

---

Calculating Net Present Value (NPV) at 20%

If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 20 %	Discounted Cash Flows
Year 0	(10008770)	-10008770	-	-
Year 1	3461520	-6547250	3461520	0.8333	2884600
Year 2	3982295	-2564955	7443815	0.6944	2765483
Year 3	3960119	1395164	11403934	0.5787	2291736
Year 4	3250596	4645760	14654530	0.4823	1567610
TOTAL					9509428

The Net NPV after 4 years is -499342

At 20% discount rate the NPV is negative (9509428 - 10008770 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Pharmaxis Commercialization to discount cash flow at lower discount rates such as 15%.

Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Pharmaxis Commercialization has a NPV value higher than Zero then finance managers at Pharmaxis Commercialization can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Pharmaxis Commercialization, then the stock price of the Pharmaxis Commercialization should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Pharmaxis Commercialization should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

What can impact the cash flow of the project.

Understanding of risks involved in the project.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

What will be a multi year spillover effect of various taxation regulations.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.

---

Negotiation Strategy of Pharmaxis: A Star Performer at Commercialization Crossroads

References & Further Readings

Deepak Sardana, Don Scott-Kemmis (2018), "Pharmaxis: A Star Performer at Commercialization Crossroads Harvard Business Review Case Study. Published by HBR Publications.